언어 선택

TNFSF11

TNFSF11 분자 정보

영어 이름	Tumor necrosis factor ligand superfamily member 11	시판 약물 수	19
임상 약물 수	12	표적 별명	Osteoclast differentiation factor，TRANCE，TNFSF11，TNF-related activation-induced cytokine，Tumor necrosis factor ligand superfamily member 11，CD254，TNF Superfamily Member 11，Osteoprotegerin Ligand，Receptor Activator Of Nuclear Factor Kappa B Ligand，Tumor Necrosis Factor Superfamily Member 11，ODF，RANKL，OPGL，CD254 Antigen，HRANKL2，TNLG6B，OPTB2，SOdf，RANK Ligand，Tumor Necrosis Factor (Ligand) Superfamily， Member 11，Receptor Activator Of Nuclear Factor Kappa-B Ligand，Tumor Necrosis Factor Ligand 6B
최고 연구 개발 단계	Approved

영어 이름	Tumor necrosis factor ligand superfamily member 11
표적 별명	Osteoclast differentiation factor，TRANCE，TNFSF11，TNF-related activation-induced cytokine，Tumor necrosis factor ligand superfamily member 11，CD254，TNF Superfamily Member 11，Osteoprotegerin Ligand，Receptor Activator Of Nuclear Factor Kappa B Ligand，Tumor Necrosis Factor Superfamily Member 11，ODF，RANKL，OPGL，CD254 Antigen，HRANKL2，TNLG6B，OPTB2，SOdf，RANK Ligand，Tumor Necrosis Factor (Ligand) Superfamily， Member 11，Receptor Activator Of Nuclear Factor Kappa-B Ligand，Tumor Necrosis Factor Ligand 6B
시판 약물 수	19
임상 약물 수	12
최고 연구 개발 단계	Approved

TNFSF11 제품 목록

속성
Protein (9)
제품 라이브러리
온라인 (9)
종
Human (5)Rat (1)Cynomolgus (2)Rhesus macaque (1)
태그
His Tag (3)Fc Tag (2)Avi Tag & Fc Tag (1)His Tag & Avi Tag (2)Tag Free (1)
마커
Unconjugated (6)Biotin-labeled (3)

제품 번호	종	발현 시스템	제품 설명
HOT RAL-H5217	Human	HEK293	Human TNFSF11 / RANKL / CD254 Protein, premium grade
HOT RAL-H5240	Human	HEK293	Human TNFSF11 / RANKL / CD254 Protein, His Tag, active trimer, low endotoxin (MALS verified)
HOT RAL-H82Q5	Human	HEK293	Biotinylated Human TNFSF11 / RANKL / CD254 Protein, His,Avitag™, active trimer (MALS verified)
RAL-H5265	Human	HEK293	Human TNFSF11 / RANKL / CD254 Protein, Fc Tag
RAL-H82F9	Human	HEK293	Biotinylated Human TNFSF11 / RANKL / CD254 Protein, Avitag™,Fc Tag
RAL-C5243	Cynomolgus	HEK293	Cynomolgus TNFSF11 / RANKL / CD254 Protein, His Tag, active trimer (MALS verified)
RAL-C5263	Cynomolgus	HEK293	Cynomolgus TNFSF11 / RANKL / CD254 Protein, Fc Tag
RAL-R5243	Rhesus macaque	HEK293	Rhesus macaque TNFSF11 / RANKL / CD254 Protein, His Tag (HPLC verified)
RAL-R82Q9	Rat	HEK293	Biotinylated Rat TNFSF11 / RANKL / CD254 Protein, His,Avitag™

총 수량9

TNFSF11분자 배경

Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.

TNFSF11분자 별명

RANKL,CD254,TRANCE,OPGL,ODF

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Denosumab biosimilar(Shanghai Hansoh)	HS-20090; HS-20090-2	Phase 3 Clinical	Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd	Bone Diseases; Bone metastases; Giant Cell Tumor of Bone; Hypercalcemia; Multiple Myeloma; Neoplasms; Nutritional and Metabolic Diseases; Osteoporosis, Postmenopausal; Solid tumours	상세
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical)		Phase 3 Clinical	Qilu Pharmaceutical Co Ltd	Neoplasms; Osteoporosis, Postmenopausal	상세
Denosumab biosimilar (GlycoNex)	SPD8; SPD-8	Phase 3 Clinical	Glyconex Inc	Neoplasms; Osteoporosis	상세
Denosumab biosimilar (Hetero Biopharma)		Phase 3 Clinical	Hetero Biopharma Ltd	Solid tumours	상세
Denosumab biosimilar(Curateq Biologics)	BP-16	Phase 3 Clinical	CuraTeQ Biologics Pvt Ltd	Osteoporosis, Postmenopausal	상세
Recombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke)		Phase 3 Clinical	Jiangsu Pacific Minok Biopharmaceutical Co., Ltd.	Osteoporosis, Postmenopausal	상세
SHR-2017	SHR-2017; SHR2017	Phase 2 Clinical	Suzhou Suncadia Biopharmaceuticals Co Ltd	Bone metastases; Multiple Myeloma; Osteoporosis; Solid tumours	상세
LZM-004	LZM-004	Phase 1 Clinical	Livzon(Group) Pharmaceutical Factory	Bone metastases	상세
Recombinant human anti-RANKL antibody (Innovent Biologics)	IBI-307	Phase 1 Clinical		Osteoporosis	상세
GB-223	GB-223; GB223	Phase 1 Clinical	Genor Biopharma Co Ltd	Bone metastases; Bone Neoplasms; Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal; Solid tumours	상세
Denosumab biosimilar (Kpc Pharmaceuticals)	MV-088	Phase 1 Clinical	Kpc Pharmaceuticals Inc	Osteoporosis, Postmenopausal	상세
Denosumab biosimilar (Zhejiang Hisun)	HS629	Phase 1 Clinical	Zhejiang Hisun Pharmaceutical Co Ltd	Bone metastases; Solid tumours	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Denosumab biosimilar (Teva Pharmaceutical)	TVB-009P; TVB-009	Approved	Teva Pharmaceutical Industries Ltd	PONLIMSI, DEGEVMA	EU	Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis; Giant Cell Tumor of Bone; Neoplasms, Bone Tissue	Teva Gmbh	2025-11-17	Bone Neoplasms; Bone Resorption; Giant Cell Tumor of Bone; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal	상세
Denosumab biosimilar (Henlius)	HLX14; HLX-14	Approved		Bilprevda, Bildyos	United States	Hypercalcemia; Giant Cell Tumors; Bone metastases; Osteoporosis, Postmenopausal	Shanghai Henlius Biotech Inc	2025-08-29	Arthritis, Rheumatoid; Bone metastases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Fractures, Bone; Giant Cell Tumor of Bone; Giant Cell Tumors; Glucocorticoid-induced osteoporosis; Hypercalcemia; Multiple Myeloma; Neoplasm Metastasis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal; Prostatic Neoplasms	상세
Narlumosbart	JMT-103	Approved	Shanghai Jmt-Bio Inc	津立泰, 津立生	Mainland China	Giant Cell Tumor of Bone	Shanghai Jmt-Bio Inc	2023-09-05	Bone Diseases; Bone metastases; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Hypercalcemia; Multiple Myeloma; Neoplasms; Osteoporosis; Osteoporosis, Postmenopausal; Solid tumours	상세
Denosumab biosimilar (Mabwell)	9-MW-0311; 9MW0321; 9-MW0321; 9MW-0321; 9-MW-0321; TK-006; MW-032; MW-031; 9MW0311; 9-MW0311; 9MW-0311	Approved	Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd	迈利舒, 迈卫健, MAIWEIJIAN, MAILISHU	Mainland China	Osteoporosis, Postmenopausal	Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd	2023-03-28	Bone metastases; Bone Neoplasms; Breast Neoplasms; Giant Cell Tumor of Bone; Osteoporosis; Osteoporosis, Postmenopausal; Solid tumours	상세
Denosumab biosimilar (Qilu Pharma)	QL-1206	Approved	Qilu Pharmaceutical Co Ltd	鲁可欣	Mainland China	Osteoporosis, Postmenopausal	Qilu Pharmaceutical Co Ltd	2023-09-28	Bone metastases; Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal; Solid tumours	상세
Denosumab biosimilar (Boan Biopharma/Luye)	LY-01011; BA-1102; BA-6101; LY-06006	Approved	Shandong Boan Biotechnology Co Ltd	博洛加, Boluojia, Boyoubei, 博优倍	Mainland China	Osteoporosis, Postmenopausal	Shandong Boan Biotechnology Co Ltd	2022-11-08	Bone metastases; Bone Neoplasms; Giant Cell Tumor of Bone; Neoplasm Metastasis; Neoplasms; Osteoporosis; Osteoporosis, Postmenopausal; Solid tumours	상세
Denosumab biosimilar (Accord Healthcare)		Approved	Accord Healthcare Slu	Jubereq, Osvyrti	EU	Osteoporosis; Neoplasms, Bone Tissue; Giant Cell Tumor of Bone; Bone Resorption; Osteoporosis, Postmenopausal	Accord Healthcare Slu	2025-05-26	Bone metastases; Bone Resorption; Giant Cell Tumor of Bone; Hypercalcemia; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal	상세
Denosumab	NSC-744010; AMG-162	Approved	Amgen Inc	Prolia, Xgeva, Pralia, Ranmark, 普罗力	EU	Osteoporosis, Postmenopausal	Amgen Europe Bv	2010-05-26	Anorexia Nervosa; Arthritis, Rheumatoid; Arthropathy, Neurogenic; Bone Cysts, Aneurysmal; Bone Diseases; Bone Diseases, Metabolic; Bone metastases; Bone Neoplasms; Breast Diseases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Cataract; Chondroblastoma; Colonic Neoplasms; Crohn Disease; Endocrine Gland Neoplasms; Feeding and Eating Disorders; Fibroma; Fibrous Dysplasia of Bone; Fractures, Bone; Giant Cell Tumor of Bone; Giant Cell Tumors; Glucocorticoid-induced osteoporosis; Granuloma, Giant Cell; Head and Neck Neoplasms; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypercalcemia; Kidney Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Osteoarthritis; Osteoarthritis, Knee; Osteoblastoma; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis	상세
Denosumab biosimilar(Enzene Biosciences)	ENZ-215	Approved	Enzene Biosciences Ltd	Osqay	EU	Bone Resorption	Theramex Ireland Ltd	2026-01-08	Bone Resorption; Osteoporosis, Postmenopausal	상세
Denosumab biosimilar (Alvotech Swiss)	AVT-03; AVT03	Approved	Alvotech Swiss Ag	Acvybra, Xbonzy	EU	Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal; Bone Resorption; Neoplasms, Bone Tissue; Osteoporosis	Stada Arzneimittel Ag, Reddy Holding Gmbh	2025-11-17	Bone Resorption; Giant Cell Tumor of Bone; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal	상세
Denosumab biosimilar(Mabxience)	MB-09	Approved	Mabxience Sa	Zadenvi, Izamby, Enwylma, Denbrayce	EU	Neoplasms, Bone Tissue; Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis; Giant Cell Tumor of Bone	Zentiva Ks, Mabxience Research SL	2025-06-26	Bone Diseases; Bone Resorption; Fractures, Bone; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Hypercalcemia; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal	상세
Denosumab biosimilar (Biocon Biologics)	Bmab-1000	Approved	Biocon Ltd	Vevzuo, Evfraxy	EU	Neoplasms, Bone Tissue; Giant Cell Tumor of Bone	Biosimilar Collaborations Ireland Ltd	2025-06-25	Bone metastases; Bone Resorption; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal; Prostatic Neoplasms	상세
Denosumab biosimilar(Reliance Life Sciences)	R-TPR-045	Approved	Reliance Life Sciences	DenosuRel	India	Osteoporosis, Postmenopausal; Bone metastases	Reliance Life Sciences	2022-02-01	Bone metastases; Osteoporosis, Postmenopausal	상세
Denosumab biosimilar (Gedeon Richter)	RGB-14-P	Approved	Gedeon Richter Plc	ENOBY, XTRENBO, Yaxwer, Junod	EU	Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis; Giant Cell Tumor of Bone; Neoplasms, Bone Tissue	Gedeon Richter Plc	2025-06-23	Bone metastases; Bone Resorption; Breast Neoplasms; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal; Prostatic Neoplasms	상세
Denosumab biosimilar(Fresenius Kabi)	FKS-518	Approved	Fresenius Kabi Swissbiosim Gmbh	BOMYNTRA, CONEXXENCE	United States	Giant Cell Tumor of Bone; Hypercalcemia; Bone metastases	Fresenius Kabi Usa Llc	2025-03-25	Bone metastases; Bone Resorption; Giant Cell Tumor of Bone; Hypercalcemia; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal	상세
Denosumab biosimilar (Samsung Bioepis)	SB-16	Approved	Samsung Bioepis Co Ltd	Ospomyv, Xbryk, XBRYK, OBODENCE	EU	Neoplasms, Bone Tissue; Giant Cell Tumor of Bone; Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal	Samsung Bioepis Nl Bv	2025-02-12	Bone Resorption; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal	상세
Denosumab biosimilar (Celltrion)	CT-P41	Approved	Celltrion Inc	Stoboclo, Osenvelt	EU	Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis; Neoplasms, Bone Tissue; Giant Cell Tumor of Bone	Celltrion Healthcare Hungary Kft	2025-02-14	Bone Resorption; Breast Neoplasms; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal; Prostatic Neoplasms	상세
Denosumab biosimilar (Sandoz)	GP-2411	Approved	Novartis Pharma Ag, Sandoz	Jubbonti®, Wyost®	United States	Osteoporosis, Postmenopausal; Osteoporosis; Glucocorticoid-induced osteoporosis	Sandoz, Sandoz Inc	2024-03-05	Bone Resorption; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal	상세
Denosumab biosimilar (Alphamab)	KN-012	Approved	Suzhou Alphamab Co Ltd		Mainland China	Osteoporosis, Postmenopausal	Philippine Biological Technology (Jilin) Co Ltd, Alphamab Jilin Co Ltd	2024-09-03	Osteoporosis, Postmenopausal	상세